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Background. The choice of preferred regimens for human immunodeﬁciency virus postexposure prophylaxis
(PEP) has evolved over the last 2 decades as more data have become available regarding the safety and tolerability
of newer antiretroviral drugs. We undertook a systematic review to assess the safety and efﬁcacy of antiretroviral
options for PEP to inform the World Health Organization guideline revision process.
Methods. Four databases were searched up to 1 June 2014 for studies reporting outcomes associated with spe-
ciﬁc PEP regimens. Data on PEP completion and discontinuation due to adverse events was extracted and pooled
estimates were obtained using random-effects meta-analyses.
Results. Fifteen studies (1830 PEP initiations) provided evaluable information on 2-drug regimens (zidovudine
[ZDV]- or tenofovir [TDF]-based regimens), and 10 studies (1755 initiations) provided evaluable information on the
third drug, which was usually a protease inhibitor. The overall quality of the evidence was rated as very low. For the 2-
drug regimen, PEP completion rates were 78.4% (95% conﬁdence interval [CI], 66.1%–90.7%) for people receiving a
TDF-based regimen and 58.8% (95% CI, 47.2%–70.4%) for a ZDV-based regimen; the rate of PEP discontinuation
due to an adverse event was lower among people taking TDF-based PEP (0.3%; 95% CI, 0%–1.1%) vs a ZDV-based
regimen (3.2%; 95% CI, 1.5%–4.9%). For the 3-drug comparison, PEP completion rates were highest for the
TDF-based regimens (TDF+emtricitabine [FTC]+lopinavir/ritonavir [LPV/r], 71.1%; 95% CI, 43.6%–98.6%; TDF+
FTC+raltegravir [RAL], 74.7%; 95% CI, 41.4%–100%; TDF+FTC+ boosted darunavir [DRV/r], 93.9%; 95% CI,
90.2%–97.7%) and lowest for ZDV+ lamivudine [3TC]+LPV/r (59.1%; 95% CI, 36.2%–82.0%). Discontinuations
due to adverse drug reactions were lowest for TDF+FTC+RAL (1.9%; 95% CI, 0%–3.8%) and highest for ZDV+3TC+
boosted atazanavir (21.2%; 95% CI, 13.5%–30.0%).
Conclusions. The ﬁndings of this review provide evidence supporting the use of coformulated TDF and 3TC/
FTC as preferred backbone drugs for PEP. Choice of third drug will depend on setting; for resource-limited settings,
LPV/r is a reasonable choice, pending the improved availability of better-tolerated drugs with less potential for drug–
drug interactions.
Keywords. antiretroviral; adverse events; postexposure prophylaxis; tolerability; safety.
Guidelines for postexposure prophylaxis (PEP) to pre-
vent human immunodeﬁciency virus (HIV) infection
issued by the World Health Organization (WHO) in
2007 recommended zidovudine (ZDV) and lamivudine
(3TC) as backbone drugs for PEP with a third drug, pref-
erably ritonavir-boosted lopinavir (LPV/r), added ac-
cording to exposure risk and the risk of viral drug
resistance [1]. Since then, more data have become avail-
able on the safety and tolerability of newer antiretroviral
drugs when used for treating HIV-infected individuals;
recommendations for use in HIV-uninfected persons
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have evolved parallel to this development. PEP guidelines in the
United States and Europe have recently been revised to recom-
mend tenofovir (TDF) and emtricitabine (FTC) as preferred
backbone drugs, with either a protease inhibitor [2] or an inte-
grase inhibitor recommended as the third drug [3, 4].
The use of antiretroviral drugs for PEP differs from therapy
in a number of important ways that can inﬂuence drug choice.
PEP is given to HIV-uninfected immunocompetent individuals,
for a limited duration (28 days), to individuals who may have
been exposed to HIV as a result of an acute, and often traumatic,
event (in particular sexual assault). Nevertheless, to improve ac-
cess and simplify prescribing, particularly in resource-limited
settings, it is desirable to align guideline recommendations re-
garding the use of antiretroviral drugs for PEP with those rec-
ommended for treatment.
To update WHO recommendations on drug choice for PEP,
we undertook a systematic review to assess the safety and efﬁca-
cy of antiretroviral options for PEP.
METHODS
Search Strategy and Study Selection Process
An initial search was carried out to assess outcomes associated
with PEP among adults, irrespective of exposure type. Four da-
tabases—Medline via PubMed, Embase, the Cochrane Database
of Systematic Reviews, and Lilacs—were searched from incep-
tion to 1 December 2013 according to a predeﬁned protocol;
this search was updated in PubMed to 1 June 2014. Abstracts
of all conferences of the International AIDS Society were
searched from 2010 to 2013, and the Conference on Retrovirus-
es and Opportunistic Infections for 2014 (abstracts for prior
conferences were not available online) [5].
Two investigators (N. F., C. I.), working independently,
scanned all abstracts and independently assessed potentially el-
igible studies as full text. Consensus was sought prior to ﬁnal
inclusion; in case of disagreement, a third investigator (Z. S.)
was consulted. Randomized trials and prospective observational
studies reporting outcomes among >10 patients offered PEP
were eligible for inclusion irrespective of exposure type provided
that information was available on outcomes associated with
speciﬁc PEP regimens. No language or geographical limits
were applied.
Data were extracted independently and in duplicate using a
piloted data extraction tool. Information was collected on
study country, study population, exposure type, and regimens
used. Owing to the difﬁculty in establishing efﬁcacy of PEP in
human studies (the HIV status of source and exposed is often
not reported), the primary outcome for this review was discon-
tinuation due to adverse events; secondary outcomes included
PEP completion rates (deﬁned as completing a full 28-day
course of PEP), severe adverse events, and mortality due to
adverse events. Studies were grouped to ensure comparability
between regimens, and for the purposes of this review, lamivu-
dine (3TC) and FTC were considered interchangeable, consis-
tent with evidence from randomized trials [6]. Studies that
reported outcomes for drugs that are no longer recommended
for treatment were excluded from the ﬁnal review. Data were
also extracted to assess risk of bias according to predeﬁned cri-
teria indicative of study quality for randomized trials and obser-
vational studies (Supplementary Tables 1 and 2). The overall
quality of the evidence for the outcome of treatment discontin-
uations due to adverse events was assessed using the Grading of
Recommendations Assessment, Development and Evaluation
(GRADE) framework [7].
Data Analysis
Point estimates and 95% conﬁdence intervals (CIs) were calcu-
lated for the proportion of patients experiencing each outcome.
Patients who discontinued PEP because it was subsequently
found not to be needed (either because they were found to al-
ready be HIV infected or because the source was found to be
HIV uninfected) were excluded from the denominator for
assessing PEP completion rates. Data were transformed to sta-
bilize the variance in the raw proportions and pooled after back-
transformation using random-effects meta-analysis [8, 9]. Data
from randomized trials and prospective observational studies
were pooled together because adverse drug reactions are gener-
ally rare events, and no important differences in the reporting of
these events have been observed between randomized trials and
observational studies [10]. Because the drug comparisons of the
proportion of patients experiencing adverse events are from
separate cohorts, pooled relative-effect measures were not
determined. All analyses were conducted using Stata version
12.0 (StataCorp, College Station, Texas) and GRADE Pro
(www.gradeworkinggroup.org).
RESULTS
From an initial assessment of 97 studies reporting outcomes of
individuals receiving PEP, 15 studies (1830 initiations) provid-
ed evaluable information on 2-drug regimens [11–25], and 10
studies (1755 initiations) provided information on the third
drug [17, 26–34] across a range of exposures. The remaining
studies were excluded for 1 or more of the following reasons:
retrospective study design, outcomes not disaggregated by reg-
imen, or regimens not reported. Data from studies reporting
PEP outcomes using stavudine and nelﬁnavir were not includ-
ed in this review because these drugs are no longer recom-
mended for treatment [25, 26, 35]. Nevirapine was also
excluded from review because, despite being widely used for
treatment, there are established concerns regarding severe
and potentially fatal adverse events attributed to nevirapine
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when used as part of PEP [36]. Among the evaluated studies, 4
studies were randomized trials [11, 27, 28, 37] and the rest were
prospective observational cohorts. The study selection process
is outlined in Figure 1 and study characteristics are summa-
rized in Table 1.
The overall quality of the evidence was rated as very low, with
the main methodological concerns relating to inconsistency (ie,
nonoverlapping CIs between studies led to uncertainty in
pooled estimates) and imprecision (ie, wide CIs for individual
estimates) (Supplementary Table 1).
For the 2-drug regimen comparisons, 12 studies (10 observa-
tional studies and 2 randomized controlled trials [RCTs] assess-
ing adherence interventions) reported outcomes of ZDV and
3TC, and 3 observational studies reported outcomes of TDF
and FTC. Pooled PEP completion rates were 78.4% (95% CI,
66.1%–90.7%) for people receiving a TDF-based regimen and
58.8% (95% CI, 47.2%–70.4%) for people receiving a ZDV-
based regimen. Similarly, the pooled proportion of PEP discon-
tinuation due to adverse events was lower among people taking
TDF-based PEP (0.3%; 95% CI, 0%–1.1%) vs a ZDV regimen
(3.2%; 95% CI, 1.5%–4.9%).
For the 3-drug comparison, 7 different comparisons were avail-
able: ZDV+3TC+atazanavir (ATV) (1 prospective cohort study),
ZDV+3TC+boosted ATV (ATV/r) (2 prospective cohort studies),
ZDV+3TC+TDF (1 prospective study), ZDV+3TC +boosted
lopinavir (LPV/r) (4 prospective cohort studies and 1 RCT), TDF-
+FTC+LPV/r (1 prospective cohort study and 1 RCT), TDF+FTC
+raltegravir (RAL) (3 prospective cohort studies), and TDF+FTC-
+boosted darunavir (DRV/r) (1 RCT). No studies provided evalu-
able data on the use of efavirenz in PEP. PEP completion rates were
lowest for ZDV+3TC+LPV/r (59.1%; 95% CI, 36.2%–82.0%) and
highest for the TDF-based regimens. Discontinuations were lowest
for TDF+FTC+RAL (1.9%; 95% CI, 0%–3.8%) and highest for
ZDV+3TC+TDF (18.7%; 95% CI, 11.8%–25.7%).
No studies reported any cases of mortality due to adverse
drug events. PEP failure as determined by HIV seroconversion
was rare, and could not be compared across regimens because of
the paucity of events and different protocols for longer-term
Figure 1. Study selection process. Abbreviation: PEP, postexposure prophylaxis.
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monitoring after PEP provision. Pooled completion rates are
summarized in Figure 2.
DISCUSSION
This is the ﬁrst systematic review of completion and discontin-
uation rates associated with different speciﬁc regimens used for
PEP. The outcomes of this review suggest that for the choice of
ﬁrst 2 drugs for PEP, TDF combined (preferably coformulated)
with 3TC or FTC may improve completion rates and result in
fewer treatment discontinuations due to adverse events and
fewer new HIV infections compared to regimens including
ZDV. This choice is further supported by the good tolerability
of these drugs in trials of preexposure prophylaxis of HIV-neg-
ative individuals [38, 39].
The choice of third drug is less clear, and will depend on con-
siderations of short-term tolerability (the main reason why ﬁrst-
generation nonnucleoside reverse transcriptase inhibitors were
never recommended for PEP use), cost, availability, and the
possible risk of transmitted drug resistance in certain contexts.
In resource-limited settings, LPV/r and ATV/r are both recom-
mended for the management of HIV-infected patients failing
ﬁrst-line antiretroviral therapy, and hence would be familiar
drugs to use for PEP. Of the 2, boosted LPV/r is more widely
available, has few concerns regarding drug–drug interactions,
and from this review appears to be better tolerated in PEP, al-
though this ﬁnding is based on very low-quality evidence.
In well-resourced settings, there has been a recent policy shift
toward combining TDF and FTC with RAL as the third drug for
PEP [3]. The ﬁndings of this review support this choice, al-
though again the data are limited and the quality of the evidence
is very low. The availability of RAL is much more limited in re-
source-limited settings, where this drug is more expensive and
generally reserved for third-line antiretroviral therapy. Moreover,
RAL is currently recommended to be prescribed twice daily,
which may affect adherence [40]. Other drugs with good
Table 1. Characteristics of Included Studies
Study, First Author Design Setting No. Receiving PEP Exposure Regimen
Abrahams [11] RCT (adherence support) South Africa 253 Sexual assault ZDV+3TC
Garcia [12] Prospective cohort Brazil 278 Sexual assault ZDV+3TC
Neu [18] Prospective cohort United States 33 Sexual assault ZDV+3TC
Kim [14] Prospective cohort South Africa 195 Sexual assault ZDV+3TC
Roland [37] RCT (adherence support) South Africa 457 Sexual assault ZDV+3TC
Speight [22] Prospective cohort Kenya 88 Sexual assault ZDV+3TC
Kahn [13] Prospective cohort United States 395 Nonoccupational ZDV+3TC
Schechter [20] Prospective cohort Brazil 109 Nonoccupational ZDV+3TC
Shoptaw [21] Prospective cohort United States 98 Nonoccupational ZDV+3TC
Winston [25] Prospective cohort Australia 261 Nonoccupational ZDV+3TC
Swotinsky [23] Prospective cohort United States 68 Occupational ZDV+3TC
Wang [24] Prospective cohort United States 380 Occupational ZDV+3TC
Landovitz [15] Prospective cohort United States 35 Nonoccupational TDF+ FTC
Mayer [16] Prospective cohort United States 371 Nonoccupational TDF+ FTC
ZDV+3TC
McAllister [17] Prospective cohort Australia 125 Nonoccupational TDF+ FTC
TDF+FTC+RAL
Diaz-Brito [27] RCT (drug regimens) Spain 200 Occupational and nonoccupational ZDV+3TC+ATV
ZDV+3TC+LPV/r
Sonder [32] Prospective cohort Netherlands 292 Occupational ZDV+3TC+ATV
Burty [26] Prospective cohort France 46 Occupational and nonoccupational ZDV+3TC+ATV/r
Fätkenheuer [28] RCT (drug regimens) Germany 306 Occupational and nonoccupational TDF+FTC+DRV/r
TDF+FTC+LPV/r
Loufty [29] Prospective cohort Canada 347 Sexual assault ZDV+3TC+LPV/r
Rabaud [31] Prospective cohort France 251 Occupational and nonoccupational ZDV+3TC+LPV/r
Tan [33] Prospective cohort Canada 124 Occupational and nonoccupational TDF+FTC+LPV/r
Tosini [34] Prospective cohort France 249 Occupational and nonoccupational TDF+FTC+LPV/r
ZDV+3TC+LPV/r
Mayer [30] Prospective cohort United States 100 Nonoccupational TDF+FTC+RAL
Abbreviations: 3TC, lamivudine; ATV, atazanavir; ATV/r, ritonavir-boosted atazanavir; DRV/r, ritonavir-boosted darunavir; FTC, emtricitabine; LPV/r, ritonavir-boosted
lopinavir; PEP, postexposure prophylaxis; RAL, raltegravir; RCT, randomized controlled trial; TDF, tenofovir; ZDV, zidovudine.
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tolerability proﬁles, prescribed once daily, including elvitegravir/
cobicistat, dolutegravir, and rilpivirine, each of which are recom-
mended as ﬁrst-line therapy in some countries (although the risk
of severe hypersensitivity is not yet excluded in HIV-uninfected
patients) [41], and low-dose efavirenz [42], may be future candi-
date drugs for PEP, but data on their use in HIV-uninfected in-
dividuals is needed to support the development of future
recommendations.
Strengths of this review include a broad search strategy that
identiﬁed a large number of studies reporting outcomes of peo-
ple initiating PEP across a range of settings and exposures. Pub-
lication bias is a concern with all systematic reviews. We
included conference abstract databases for recent years in an at-
tempt to identify studies that may have been recently completed
but not yet published in full. Another limitation is the limited
amount of information informing reasons for differences in PEP
Figure 2. Pooled proportion of individuals completing postexposure prophylaxis (PEP). Not all studies [11] contributed data on completion rates. Abbre-
viations: 3TC, lamivudine; ATV, atazanavir; ATV/r, ritonavir-boosted atazanavir; CI, conﬁdence interval; DRV/r, ritonavir-boosted darunavir; FTC, emtricita-
bine; LPV/r, ritonavir-boosted lopinavir; RAL, raltegravir; TDF, tenofovir; ZDV, zidovudine.
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completion rates, which may be inﬂuenced by factors other than
drug regimen including exposure type, adherence support, and
prior use. The main limitation is that the majority of identiﬁed
studies could not be included in the ﬁnal analysis either because
they were rated as having too high a risk of bias (retrospective
study design) or did not provide sufﬁcient information to associate
outcomes with speciﬁc regimens. This underscores the need for
high-quality studies to inform regimen choice for PEP and more
careful reporting of outcome data disaggregated by PEP regimen.
Another limitation relates to the fact that other factors may inﬂu-
ence PEP completion rates, including exposure type and patient
population (completion rates are known to be lower for exposures
following sexual assault and for adolescents [5]). We were unable
to assess this formally due to the limited number of studies con-
tributing to each drug comparison, but 7 studies included in this
review provided information on different regimens within the
same patient population [17, 26, 27, 28, 30, 34, 37].
In conclusion, the ﬁndings of this review provide evidence
supporting TDF combined with 3TC or FTC as preferred back-
bone drugs for PEP. Choice of third drug will depend on setting;
for resource-limited settings, LPV/r is a reasonable choice,
pending the improved availability of better-tolerated drugs,
with less potential for drug–drug interactions.
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